Antibiotics
Antibiotic resistance creates a severe problem in public health. Although some bacteria can cause serious diseases, most of them are resistant to the commonly available antibiotics. The following bacteria have developed resistance to antibiotics. Vancomycin-resistant Enterococcus (VRE), carbapenem-resistant Enterobacteriaceae (CRE) gut bacteria, methicillin-resistant Staphylococcus aureus (MRSA), and multi-drug-resistant Mycobacterium tuberculosis (MDR-TB).
Class of Antibiotics to which the Bacteria is Resistant
Vancomycin-resistant Enterococcus (VRE) is resistant to doxycycline, rifampin, and chloramphenicol. These antibiotics belong to the class of tetracycline. The class is categorized due to its protein synthesis indictor that inhibits the mechanism of action on the bacterial infection [1] The bacteria have a genome placidity that allow them to utilise plasmids, insertion sequence and transposon to attain and transfer resistant elements efficiently. Thus, tetracycline is a class of medication that helps treat and manage different bacterial infections.
Carbapenem resistant Enterobacteriacea (CRE) gut bacteria is resistant to carbapenem. The antibiotic is a combination of polymyxins, tigecycline, fosfomycin, and ceftazidime. The antibiotics belong to the class beta-lactam antibiotic that exhibits activity against anaerobic and aerobic gram-positive and gram-negative organisms. The antibiotics have a broad antimicrobial spectrum that acts against several aerobic and anaerobic pathogens [2]. However, Carbapenem-resistant Enterobacteriaceae has been resistant to this antibiotic.
Vancomycin or daptomycin are the antibiotics for treating invasive infections due to Methicillin-resistant Staphylococcus aureus (MRSA). The antibiotics belong to the class of Penicillinase-resistant penicillins because they inhibit the synthesis of cell walls and disrupt the permeability of cell membrane [3]. Regardless of the potency of the antibiotics, MRSA is mainly resistant.
Multi-drug resistant Mycobacterium tuberculosis (MDR-TB) is resistant to a combination of later-generation fluoroquinolones such as moxifloxacin or gatifloxacin. The antibiotics belong to the class of fluoroquinolones because of their broad spectrum of antibacterial activity against atypical organisms and anaerobes [4]. The antibiotics regimen is mainly on a six-month plan where the doctor prescribes these antibiotics for twenty-eight weeks.
Mechanism of Resistance
The resistance of Multidrug-resistant Mycobacterium tuberculosis emerges through different mechanisms. The bacteria are resistant to antibiotics because of the ability to limit the number of compounds available in the antibiotics. The intrinsic resistance occurs due to the mechanisms that produce thick and waxy hydrophobic cells to degrade the drug and modify enzymes [5]. Therefore, people who contract Multidrug-resistant Mycobacterium tuberculosis and get infections tend to resist medication that includes isoniazid and rifampin, the most potent drugs for treating tuberculosis. Due to this resistance, medical practitioners insist on combining first-line anti-tuberculosis agents that form the core treatment regimen.
Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to these antibiotics because of their differentiating attributes to healthcare-associated infections. In cases of high MRSA, the bacteria isolates the elements of antibiotics rendering it infective. Thus, there have been several companies that have manufactured different antibiotics with differing components [4].
Carbapenem-resistant Enterobacteriaceae (CRE) resists antibiotics because of their ability to trigger enzyme production in the host. For this reason, the structural mutation triggers the pathogens to produce carbpenemasses that hydrolize carbapenem. Thus, the efflux pump and porin mutation form the primary mechanism of resistance [3].
The resistance of Enterococci is due to its incredible efficiency in attaining antimicrobial resistance. As a result, the bacteria display a variety of mechanisms that facilitate intrinsic resistance.
Work Cited
- O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infection and drug resistance. 2015;8:217.
- Lasko MJ, Nicolau DP. Carbapenem-resistant Enterobacterales: considerations for treatment in the era of new antimicrobials and evolving enzymology. Current infectious disease reports. 2020 Mar;22(3):1-2.
- Bruyndonckx R, Adriaenssens N, Hens N, Versporten A, Monnet DL, Molenberghs G, Goossens H, Weist K, Coenen S. Consumption of penicillins in the community, European Union/European Economic Area, 1997–2017. Journal of Antimicrobial Chemotherapy. 2021 Jul;76(Supplement_2):ii14-21.
- Jaka H, Rüttgerodt N, Bohne W, Mueller A, Gross U, Kasang C, Mshana SE. Helicobacter pylori mutations conferring resistance to Fluoroquinolones and clarithromycin among dyspeptic patients attending a tertiary hospital, Tanzania. Canadian Journal of Gastroenterology and Hepatology. 2019 Jul 1;2019.
- Babakhani S, Oloomi M. Transposons: the agents of antibiotic resistance in bacteria. Journal of basic microbiology. 2018 Nov;58(11):905-17.
Order an Essay Now & Get These Features For Free:
Turnitin Report
Formatting
Title Page
Citation
Outline
